Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study

P. J. Goadsby, B. M. Grosberg, A. Mauskop, R. Cady, K. A. Simmons

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Background: We sought to assess a novel, noninvasive, portable vagal nerve stimulator (nVNS) for acute treatment of migraine

Methods: Participants with migraine with or without aura were eligible for an open-label, single-arm, multiple-attack study. Up to four migraine attacks were treated with two 90-second doses, at 15-minute intervals delivered to the right cervical branch of the vagus nerve within a six-week time period. Subjects were asked to self-treat at moderate or severe pain, or after 20 minutes of mild pain.

Results: Of 30 enrolled patients (25 females, five males, median age 39), two treated no attacks, and one treated aura only, leaving a Full Analysis Set of 27 treating 80 attacks with pain. An adverse event was reported in 13 patients, notably: neck twitching (n= 1), raspy voice (n= 1) and redness at the device site (n= 1). No unanticipated, serious or severe adverse events were reported. The pain-free rate at two hours was four of 19 (21%) for the first treated attack with a moderate or severe headache at baseline. For all moderate or severe attacks at baseline, the pain-free rate was 12/54 (22%).

Conclusions: nVNS may be an effective and well-tolerated acute treatment for migraine in certain patients.

Original languageEnglish (US)
Pages (from-to)986-993
Number of pages8
JournalCephalalgia
Volume34
Issue number12
DOIs
StatePublished - Oct 27 2014

Fingerprint

Vagus Nerve Stimulation
Migraine Disorders
Pain
Migraine without Aura
Migraine with Aura
Vagus Nerve
Headache
Epilepsy
Neck
Equipment and Supplies
Therapeutics
Pain-Free

Keywords

  • acute treatment
  • Migraine
  • neuromodulation
  • vagus nerve

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Goadsby, P. J., Grosberg, B. M., Mauskop, A., Cady, R., & Simmons, K. A. (2014). Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study. Cephalalgia, 34(12), 986-993. https://doi.org/10.1177/0333102414524494

Effect of noninvasive vagus nerve stimulation on acute migraine : An open-label pilot study. / Goadsby, P. J.; Grosberg, B. M.; Mauskop, A.; Cady, R.; Simmons, K. A.

In: Cephalalgia, Vol. 34, No. 12, 27.10.2014, p. 986-993.

Research output: Contribution to journalArticle

Goadsby, PJ, Grosberg, BM, Mauskop, A, Cady, R & Simmons, KA 2014, 'Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study', Cephalalgia, vol. 34, no. 12, pp. 986-993. https://doi.org/10.1177/0333102414524494
Goadsby, P. J. ; Grosberg, B. M. ; Mauskop, A. ; Cady, R. ; Simmons, K. A. / Effect of noninvasive vagus nerve stimulation on acute migraine : An open-label pilot study. In: Cephalalgia. 2014 ; Vol. 34, No. 12. pp. 986-993.
@article{6f2efa0d46814872bc2217db029a64cb,
title = "Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study",
abstract = "Background: We sought to assess a novel, noninvasive, portable vagal nerve stimulator (nVNS) for acute treatment of migraineMethods: Participants with migraine with or without aura were eligible for an open-label, single-arm, multiple-attack study. Up to four migraine attacks were treated with two 90-second doses, at 15-minute intervals delivered to the right cervical branch of the vagus nerve within a six-week time period. Subjects were asked to self-treat at moderate or severe pain, or after 20 minutes of mild pain.Results: Of 30 enrolled patients (25 females, five males, median age 39), two treated no attacks, and one treated aura only, leaving a Full Analysis Set of 27 treating 80 attacks with pain. An adverse event was reported in 13 patients, notably: neck twitching (n= 1), raspy voice (n= 1) and redness at the device site (n= 1). No unanticipated, serious or severe adverse events were reported. The pain-free rate at two hours was four of 19 (21{\%}) for the first treated attack with a moderate or severe headache at baseline. For all moderate or severe attacks at baseline, the pain-free rate was 12/54 (22{\%}).Conclusions: nVNS may be an effective and well-tolerated acute treatment for migraine in certain patients.",
keywords = "acute treatment, Migraine, neuromodulation, vagus nerve",
author = "Goadsby, {P. J.} and Grosberg, {B. M.} and A. Mauskop and R. Cady and Simmons, {K. A.}",
year = "2014",
month = "10",
day = "27",
doi = "10.1177/0333102414524494",
language = "English (US)",
volume = "34",
pages = "986--993",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "12",

}

TY - JOUR

T1 - Effect of noninvasive vagus nerve stimulation on acute migraine

T2 - An open-label pilot study

AU - Goadsby, P. J.

AU - Grosberg, B. M.

AU - Mauskop, A.

AU - Cady, R.

AU - Simmons, K. A.

PY - 2014/10/27

Y1 - 2014/10/27

N2 - Background: We sought to assess a novel, noninvasive, portable vagal nerve stimulator (nVNS) for acute treatment of migraineMethods: Participants with migraine with or without aura were eligible for an open-label, single-arm, multiple-attack study. Up to four migraine attacks were treated with two 90-second doses, at 15-minute intervals delivered to the right cervical branch of the vagus nerve within a six-week time period. Subjects were asked to self-treat at moderate or severe pain, or after 20 minutes of mild pain.Results: Of 30 enrolled patients (25 females, five males, median age 39), two treated no attacks, and one treated aura only, leaving a Full Analysis Set of 27 treating 80 attacks with pain. An adverse event was reported in 13 patients, notably: neck twitching (n= 1), raspy voice (n= 1) and redness at the device site (n= 1). No unanticipated, serious or severe adverse events were reported. The pain-free rate at two hours was four of 19 (21%) for the first treated attack with a moderate or severe headache at baseline. For all moderate or severe attacks at baseline, the pain-free rate was 12/54 (22%).Conclusions: nVNS may be an effective and well-tolerated acute treatment for migraine in certain patients.

AB - Background: We sought to assess a novel, noninvasive, portable vagal nerve stimulator (nVNS) for acute treatment of migraineMethods: Participants with migraine with or without aura were eligible for an open-label, single-arm, multiple-attack study. Up to four migraine attacks were treated with two 90-second doses, at 15-minute intervals delivered to the right cervical branch of the vagus nerve within a six-week time period. Subjects were asked to self-treat at moderate or severe pain, or after 20 minutes of mild pain.Results: Of 30 enrolled patients (25 females, five males, median age 39), two treated no attacks, and one treated aura only, leaving a Full Analysis Set of 27 treating 80 attacks with pain. An adverse event was reported in 13 patients, notably: neck twitching (n= 1), raspy voice (n= 1) and redness at the device site (n= 1). No unanticipated, serious or severe adverse events were reported. The pain-free rate at two hours was four of 19 (21%) for the first treated attack with a moderate or severe headache at baseline. For all moderate or severe attacks at baseline, the pain-free rate was 12/54 (22%).Conclusions: nVNS may be an effective and well-tolerated acute treatment for migraine in certain patients.

KW - acute treatment

KW - Migraine

KW - neuromodulation

KW - vagus nerve

UR - http://www.scopus.com/inward/record.url?scp=84908206786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908206786&partnerID=8YFLogxK

U2 - 10.1177/0333102414524494

DO - 10.1177/0333102414524494

M3 - Article

AN - SCOPUS:84908206786

VL - 34

SP - 986

EP - 993

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 12

ER -